173 related articles for article (PubMed ID: 2767596)
1. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Slawiński M; Czarnecka H
Fortschr Med; 1989 Jul; 107(20):450-2. PubMed ID: 2767596
[TBL] [Abstract][Full Text] [Related]
2. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
Horváth M; Varsányl M; Jovanovich N; Romics L; Gerö S
Allergol Immunopathol (Madr); 1990; 18(2):95-9. PubMed ID: 2371944
[TBL] [Abstract][Full Text] [Related]
3. [Atherosclerosis treatment with etofibrate retard. New perspectives].
Degenring FH; Schatton W; Hotz W
Fortschr Med; 1983 Aug; 101(30):1391-6. PubMed ID: 6618402
[TBL] [Abstract][Full Text] [Related]
4. [Use of etofibrate in the treatment of patients with hyperlipidemia and arteriosclerosis obliterans of the legs].
Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Sławiński M; Czarnecka B
Pol Tyg Lek; 1987 Dec 21-28; 42(51-52):1643-8. PubMed ID: 3330798
[No Abstract] [Full Text] [Related]
5. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
Freyberger H; Schifferdecker E; Schatz H
Med Klin (Munich); 1994 Nov; 89(11):594-7, 633. PubMed ID: 7815987
[TBL] [Abstract][Full Text] [Related]
6. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
Słowińska R; Bochenek W; Unlot J
Pol Tyg Lek; 1983 Apr; 38(17):529-32. PubMed ID: 6356087
[No Abstract] [Full Text] [Related]
7. Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
Fincham JE; Quack G; Wülfroth P; Benadé AJ
Arzneimittelforschung; 1996 May; 46(5):519-25. PubMed ID: 8737639
[TBL] [Abstract][Full Text] [Related]
8. Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
Johnson KI; Hoppe HJ; Schatton W
Arzneimittelforschung; 1984; 34(12):1785-7. PubMed ID: 6543315
[TBL] [Abstract][Full Text] [Related]
9. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
Krüger B
Int J Clin Pharmacol Res; 1994; 14(5-6):177-83. PubMed ID: 7672874
[TBL] [Abstract][Full Text] [Related]
10. The effect of etofibrate retard, bezafibrate and procetofen.
Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
Artery; 1980; 8(2):128-33. PubMed ID: 7458677
[TBL] [Abstract][Full Text] [Related]
11. [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
Mertz DP
Fortschr Med; 1980 Dec; 98(45):1761-6. PubMed ID: 7461569
[TBL] [Abstract][Full Text] [Related]
12. Etofibrate treatment alters low density lipoprotein susceptibility to lipid peroxidation.
Wülfroth P; Richter CM; Burkard M; Huth K; Quack G
Drugs Exp Clin Res; 1992; 18(11-12):469-74. PubMed ID: 1308472
[TBL] [Abstract][Full Text] [Related]
13. Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
Badimón JJ; Padró T; Cánovas M; Vidal M; Villaverde CA
Methods Find Exp Clin Pharmacol; 1983 Nov; 5(9):613-7. PubMed ID: 6668971
[TBL] [Abstract][Full Text] [Related]
14. [Behavior of high-density lipoproteins in drug lipid-lowering treatment].
Mordasini R; Riesen W; Oster P; Riva G
Schweiz Med Wochenschr; 1982 Jan; 112(3):95-8. PubMed ID: 7058319
[TBL] [Abstract][Full Text] [Related]
15. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
Mertz DP; Loewer H; Suermann I
Med Klin; 1979 Dec; 74(51-52):1953-6. PubMed ID: 542179
[TBL] [Abstract][Full Text] [Related]
16. [Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate].
Fonseca FA; Novazzi JP; Cendoroglo MS; Duarte M; Almeida Pinto LE; Rabelo LM; da Rocha Martinez TL
Arq Bras Cardiol; 1996 Jan; 66(1):33-5. PubMed ID: 8731322
[TBL] [Abstract][Full Text] [Related]
17. [Bezafibrate and delayed action etofibrate in hyperlipidemia].
Lang PD; Vollmar J
Dtsch Med Wochenschr; 1983 Feb; 108(8):302-5. PubMed ID: 6825604
[No Abstract] [Full Text] [Related]
18. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
Emmerich KH; Poritis N; Stelmane I; Klindzane M; Erbler H; Goldsteine J; Görtelmeyer R
Klin Monbl Augenheilkd; 2009 Jul; 226(7):561-7. PubMed ID: 19644802
[TBL] [Abstract][Full Text] [Related]
19. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Jastrzebska M; Torbus-Lisiecka B; Pieczul-Mróz J; Chelstowski K; Kopciewicz J; Naruszewicz M
Int J Clin Pharmacol Res; 1999; 19(1):19-25. PubMed ID: 10450539
[TBL] [Abstract][Full Text] [Related]
20. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
Machalke K; Djaja S; Richter E
Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
[No Abstract] [Full Text] [Related]
[Next] [New Search]
